APAC Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2031

Description

List of Tables

The Asia-Pacific duchenne muscular dystrophy treatment market is expected to reach USD 1,215,876.64 thousand by 2030 from USD 331,133.48 thousand in 2022, growing at a CAGR of 18.2% in the forecast period of 2023 to 2030.

Market Segmentation

Asia-Pacific Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030.

Overview of Asia-Pacific Duchenne Muscular Dystrophy Treatment Market Dynamics

Driver
Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease
Restraint
High treatment cost of DMD disorder
Opportunity
Strategic initiatives by key market players

Market Players

Some of the key market players for Asia-Pacific duchenne muscular dystrophy treatment market are:

Sarepta Therapeutics, Inc.
Solid Biosciences Inc.
Capricor Therapeutics, Inc.
Dyne Therapeutics
BioMarin
Stealth BioTherapeutics Inc
Avidity Biosciences
ReveraGen
BioPharma, Inc.
TAIHO PHARMACEUTICAL CO., LTD.
Akashi RX
ITALFARMACO S.p.
NS Pharma, Inc.
PTC Therapeutics.
Pfizer Inc.
FibroGen, Inc.
SANTHERA PHARMACEUTICALS
F. Hoffmann-La Roche Ltd

1 INTRODUCTION 23

1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF THE ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 23
1.4 CURRENCY AND PRICING 25
1.5 LIMITATIONS 25
1.6 MARKETS COVERED 25

2 MARKET SEGMENTATION 27

2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.6 MULTIVARIATE MODELLING 34
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 34
2.8 MARKET END USER COVERAGE GRID 35
2.9 DBMR MARKET POSITION GRID 36
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39

4 PREMIUM INSIGHTS 41

4.1 PESTEL'S MODEL 42
4.2 PORTER'S FIVE FORCES MODEL 43
4.3 PRICING ANALYSIS 43

5 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: REGULATIONS 45

5.1 REGULATIONS IN U.S. 45
5.2 REGULATTIONS IN EUROPE 46
5.3 REGULATTIONS IN AUSTRALIA 46
5.4 REGULATIONS IN SOUTH AFRICA 46
5.5 REGULATIONS IN BRAZIL 47

6 MARKET OVERVIEW 48

6.1 DRIVERS 50
- 6.1.1 INCREASING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) DISEASE 50
- 6.1.2 INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER 50
- 6.1.3 RISING AWARENESS FOR DMD TREATMENTS 51
- 6.1.4 INCREASE IN THE NUMBER OF CLINICAL TRIALS IS A RECENT TREND 52
6.2 RESTRAINTS 53
- 6.2.1 LIMITED AVAILABILITY OF DMD TREATMENTS DUE TO LACK OF ADVANCE TECHNOLOGY 53
- 6.2.2 HIGH TREATMENT COST OF DMD DISORDER 54
6.3 OPPORTUNITIES 55
- 6.3.1 DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE AND INCREASING INVESTMENT 55
- 6.3.2 RISING PATIENT INCLINATION TOWARDS PERSONALIZED AND EFFECTIVE THERAPIES 55
- 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 56
- 6.3.4 SUPPORT FROM PATIENT ADVOCACY GROUPS ON THE REGULATORY APPROVAL PROCESS 56
6.4 CHALLENGES 57
- 6.4.1 LACK OF STANDARDIZATION IN DMD DIAGNOSIS 57
- 6.4.2 ETHICAL CONSIDERATIONS RELATED TO PERMANENT ALTERATION OF A PATIENT'S GENETIC CODE 58

7 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE 59

7.1 OVERVIEW 60
7.2 MOLECULAR-BASED THERAPIES 63
- 7.2.1 ANTISENSE OLIGONUCLEOTIDE THERAPY 64
  - 7.2.1.1 EXONDYS 51 64
  - 7.2.1.2 AMONDYS 45 65
  - 7.2.1.3 VYONDYS 53 65
7.3 NONSENSE MUTATION 65
7.4 STEROID THERAPY 66
- 7.4.1 PREDNISONE 66
- 7.4.2 DEFLAZACORT 66
7.5 OTHERS 67

8 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY 68

8.1 OVERVIEW 69
8.2 EXON SKIPPING APPROACH 72
- 8.2.1 MULTI-EXON SKIPPING APPROACH 72
- 8.2.2 SINGLE-EXON SKIPPING APPROACH 73
8.3 MUTATION SUPPRESSION 73
8.4 DYSTROPHIN-TARGETED THERAPIES 74
- 8.4.1 GENE THERAPIES 74
- 8.4.2 CELL THERAPIES 75
  - 8.4.2.1 Gene Editing 75
  - 8.4.2.2 Gene Addition 75

9 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 76

9.1 OVERVIEW 77
9.2 PARENTERAL 80
9.3 ORAL 81
9.4 OTHERS 82

10 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER 83

10.1 OVERVIEW 84
10.2 HOSPITALS 87
10.3 SPECIALTY CLINICS 88
10.4 HOMECARE 89
10.5 OTHERS 90

11 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 91

11.1 OVERVIEW 92
11.2 HOSPITAL PHARMACY 95
11.3 RETAIL PHARMACY 96
11.4 ONLINE PHARMACY 97

12 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION 98

12.1 ASIA-PACIFIC 100
- 12.1.1 CHINA 105
- 12.1.2 JAPAN 110
- 12.1.3 INDIA 115
- 12.1.4 SOUTH KOREA 120
- 12.1.5 AUSTRALIA 125
- 12.1.6 SINGAPORE 130
- 12.1.7 THAILAND 135
- 12.1.8 MALAYSIA 140
- 12.1.9 INDONESIA 145
- 12.1.10 PHILIPPINES 150
- 12.1.11 REST OF ASIA-PACIFIC 155

13 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 156

13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 156

14 SWOT ANALYSIS 157

15 COMPANY PROFILES 158

15.1 SAREPTA THERAPEUTICS, INC. 158
- 15.1.1 COMPANY SNAPSHOT 158
- 15.1.1 REVENUE ANALYSIS 159
- 15.1.2 COMPANY SHARE ANALYSIS 159
- 15.1.3 PRODUCT PORTFOLIO 160
- 15.1.4 PIPELINE PORTFOLIO 160
- 15.1.5 RECENT DEVELOPMENTS 160
15.2 F. HOFFMANN-LA ROCHE LTD 162
- 15.2.1 COMPANY SNAPSHOT 162
- 15.2.2 REVENUE ANALYSIS 162
- 15.2.3 COMPANY SHARE ANALYSIS 163
- 15.2.4 PRODUCT PORTFOLIO 163
- 15.2.5 PIPELINE PORTFOLIO 163
- 15.2.6 RECENT DEVELOPMENTS 163
15.3 PTC THERAPEUTICS. 164
- 15.3.1 COMPANY SNAPSHOT 164
- 15.3.2 REVENUE ANALYSIS 164
- 15.3.3 COMPANY SHARE ANALYSIS 165
- 15.3.4 PRODUCT PORTFOLIO 165
- 15.3.5 RECENT DEVELOPMENT 165
15.4 PFIZER INC. 166
- 15.4.1 COMPANY SNAPSHOT 166
- 15.4.2 REVENUE ANALYSIS 166
- 15.4.3 COMPANY SHARE ANALYSIS 167
- 15.4.4 PIPELINE PORTFOLIO 167
- 15.4.5 PRODUCT PORTFOLIO 167
- 15.4.6 RECENT DEVELOPMENT 167
15.5 AKASHI RX 168
- 15.5.1 COMPANY SNAPSHOT 168
- 15.5.2 PIPELINE PORTFOLIO 168
- 15.5.3 RECENT DEVELOPMENTS 168
15.6 AVIDITY BIOSCIENCES 169
- 15.6.1 COMPANY SNAPSHOT 169
- 15.6.2 REVENUE ANALYSIS 169
- 15.6.3 PIPELINE PORTFOLIO 170
- 15.6.4 RECENT DEVELOPMENTS 170
15.7 BIOMARIN 171
- 15.7.1 COMPANY SNAPSHOT 171
- 15.7.2 REVENUE ANALYSIS 171
- 15.7.3 PIPELINE PORTFOLIO 172
- 15.7.4 RECENT DEVELOPMENTS 172
15.8 CAPRICOR THERAPEUTICS, INC. 173
- 15.8.1 COMPANY SNAPSHOT 173
- 15.8.2 PIPELINE PORTFOLIO 173
- 15.8.3 RECENT DEVELOPMENTS 174
15.9 DYNE THERAPEUTICS 175
- 15.9.1 COMPANY SNAPSHOT 175
- 15.9.2 PIPELINE PORTFOLIO 175
- 15.9.3 RECENT DEVELOPMENTS 176
15.10 FIBROGEN, INC. 177
- 15.10.1 COMPANY SNAPSHOT 177
- 15.10.2 REVENUE ANALYSIS 177
- 15.10.3 PIPELINE PORTFOLIO 178
- 15.10.4 RECENT DEVELOPMENT 178
15.11 ITALFARMACO S.P.A. 179
- 15.11.1 COMPANY SNAPSHOT 179
- 15.11.2 PIPELINE PORTFOLIO 179
- 15.11.3 RECENT DEVELOPMENT 179
15.12 NS PHARMA, INC. 180
- 15.12.1 COMPANY SNAPSHOT 180
- 15.12.2 PIPELINE PORTFOLIO 180
- 15.12.3 RECENT DEVELOPMENTS 181
15.13 REVERAGEN BIOPHARMA, INC. 182
- 15.13.1 COMPANY SNAPSHOT 182
- 15.13.2 PIPELINE PORTFOLIO 182
- 15.13.3 RECENT DEVELOPMENT 182
15.14 SANTHERA PHARMACEUTICALS 183
- 15.14.1 COMPANY SNAPSHOT 183
- 15.14.2 REVENUE ANALYSIS 183
- 15.14.3 PIPELINE PORTFOLIO 184
- 15.14.4 RECENT DEVELOPMENT 184
15.15 TAIHO PHARMACEUTICAL CO., LTD. 185
- 15.15.1 COMPANY SNAPSHOT 185
- 15.15.2 PIPELINE PORTFOLIO 185
- 15.15.3 RECENT DEVELOPMENTS 185
15.16 SOLID BIOSCIENCES INC. 186
- 15.16.1 COMPANY SNAPSHOT 186
- 15.16.2 PIPELINE PORTFOLIO 186
- 15.16.3 RECENT DEVELOPMENT 186
15.17 STEALTH BIOTHERAPEUTICS INC 187
- 15.17.1 COMPANY SNAPSHOT 187
- 15.17.2 PIPELINE PORTFOLIO 187
- 15.17.3 RECENT DEVELOPMENT 187

16 QUESTIONNAIRE 188

17 RELATED REPORTS 191

LIST OF TABLES

TABLE 1 LIST OF PRICES FOR APPROVED DRUGS OF THE ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 44
TABLE 2 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE , 2021-2030 (USD THOUSAND) 63
TABLE 3 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
TABLE 4 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 64
TABLE 5 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 64
TABLE 6 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 7 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 8 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 9 ASIA-PACIFIC OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 10 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 71
TABLE 11 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 12 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 72
TABLE 13 ASIA-PACIFIC MUTATION SUPPRESSION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 14 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 15 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 74
TABLE 16 ASIA-PACIFIC CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 75
TABLE 17 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND) 79
TABLE 18 ASIA-PACIFIC PARENTERAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 19 ASIA-PACIFIC ORAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 20 ASIA-PACIFIC OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 21 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USERS, 2021-2030 (USD THOUSAND) 86
TABLE 22 ASIA-PACIFIC HOSPITALS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 23 ASIA-PACIFIC SPECIALITY CLINICS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 24 ASIA-PACIFIC HOMECARE IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 25 ASIA-PACIFIC OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 26 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 27 ASIA-PACIFIC HOSPITAL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 28 ASIA-PACIFIC RETAIL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
TABLE 29 ASIA-PACIFIC ONLINE PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
TABLE 30 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 100
TABLE 31 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 32 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 33 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 34 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 101
TABLE 35 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 36 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 102
TABLE 37 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 38 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 102
TABLE 39 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 103
TABLE 40 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 103
TABLE 41 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 103
TABLE 42 ASIA-PACIFIC CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 103
TABLE 43 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 104
TABLE 44 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 104
TABLE 45 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 104
TABLE 46 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 47 CHINA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 48 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 49 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 106
TABLE 50 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 106
TABLE 51 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 52 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 106
TABLE 53 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 107
TABLE 54 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 55 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 107
TABLE 56 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 107
TABLE 57 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 108
TABLE 58 CHINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 108
TABLE 59 CHINA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 108
TABLE 60 CHINA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 108
TABLE 61 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 109
TABLE 62 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 109
TABLE 63 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 109
TABLE 64 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 65 JAPAN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 66 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 67 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 111
TABLE 68 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 111
TABLE 69 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 70 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 111
TABLE 71 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 112
TABLE 72 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 73 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 112
TABLE 74 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 112
TABLE 75 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 113
TABLE 76 JAPAN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 113
TABLE 77 JAPAN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 113
TABLE 78 JAPAN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 113
TABLE 79 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 114
TABLE 80 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 81 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 82 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 83 INDIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 84 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 85 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 116
TABLE 86 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 116
TABLE 87 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 88 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 116
TABLE 89 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 117
TABLE 90 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 91 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 117
TABLE 92 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 117
TABLE 93 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 118
TABLE 94 INDIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 118
TABLE 95 INDIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 118
TABLE 96 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 119
TABLE 97 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 119
TABLE 98 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 119
TABLE 99 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 100 SOUTH KOREA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 101 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 102 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 121
TABLE 103 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 121
TABLE 104 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 105 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 121
TABLE 106 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 122
TABLE 107 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 108 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 122
TABLE 109 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 122
TABLE 110 SOUTH KOREADUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 123
TABLE 111 SOUTH KOREA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 123
TABLE 112 SOUTH KOREA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 123
TABLE 113 SOUTH KOREA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 123
TABLE 114 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 124
TABLE 115 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 124
TABLE 116 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124
TABLE 117 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 118 AUSTRALIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 119 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 120 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 126
TABLE 121 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 126
TABLE 122 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 123 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 126
TABLE 124 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 127
TABLE 125 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 126 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 127
TABLE 127 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 127
TABLE 128 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 128
TABLE 129 AUSTRALIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 128
TABLE 130 AUSTRALIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 128
TABLE 131 AUSTRALIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 128
TABLE 132 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 129
TABLE 133 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 129
TABLE 134 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 129
TABLE 135 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 136 SINGAPORE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 137 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 138 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 131
TABLE 139 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 131
TABLE 140 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 141 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 131
TABLE 142 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 132
TABLE 143 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 144 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 132
TABLE 145 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 132
TABLE 146 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 133
TABLE 147 SINGAPORE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 133
TABLE 148 SINGAPORE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 133
TABLE 149 SINGAPORE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 133
TABLE 150 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 134
TABLE 151 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 134
TABLE 152 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 134
TABLE 153 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 154 THAILAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 155 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 156 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 136
TABLE 157 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 136
TABLE 158 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 159 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 136
TABLE 160 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 137
TABLE 161 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 162 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 137
TABLE 163 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 137
TABLE 164 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 138
TABLE 165 THAILAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 138
TABLE 166 THAILAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 138
TABLE 167 THAILAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 138
TABLE 168 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 139
TABLE 169 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 139
TABLE 170 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
TABLE 171 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 172 MALAYSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 173 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 174 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 141
TABLE 175 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
TABLE 176 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 177 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 141
TABLE 178 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 142
TABLE 179 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 180 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 142
TABLE 181 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 142
TABLE 182 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 143
TABLE 183 MALAYSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 143
TABLE 184 MALAYSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 143
TABLE 185 MALAYSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 143
TABLE 186 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
TABLE 187 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
TABLE 188 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 144
TABLE 189 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 190 INDONESIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 191 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 192 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 146
TABLE 193 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 146
TABLE 194 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 195 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 146
TABLE 196 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 147
TABLE 197 INDONESIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 198 INDONESIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
TABLE 199 INDONESIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 147
TABLE 200 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
TABLE 201 INDONESIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
TABLE 202 INDONESIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
TABLE 203 INDONESIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
TABLE 204 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 149
TABLE 205 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 149
TABLE 206 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 149
TABLE 207 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 208 PHILIPPINES MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 209 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 210 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 151
TABLE 211 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 151
TABLE 212 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 213 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 151
TABLE 214 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 152
TABLE 215 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 216 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
TABLE 217 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 152
TABLE 218 PHILIPPINESDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 153
TABLE 219 PHILIPPINES EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 153
TABLE 220 PHILIPPINES DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 153
TABLE 221 PHILIPPINES CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 153
TABLE 222 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 154
TABLE 223 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 154
TABLE 224 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 154
TABLE 225 REST OF ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 27
FIGURE 2 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DATA TRIANGULATION 30
FIGURE 3 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DROC ANALYSIS 31
FIGURE 4 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS 32
FIGURE 5 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 32
FIGURE 6 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 7 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: MARKET END USER COVERAGE GRID 35
FIGURE 8 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DBMR MARKET POSITION GRID 36
FIGURE 9 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: VENDOR SHARE ANALYSIS 37
FIGURE 10 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 40
FIGURE 11 THE RISING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) AND INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET FROM 2023 TO 2030 41
FIGURE 12 MOLECULAR-BASED THERAPIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET IN 2023 AND 2030 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 49
FIGURE 14 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , 2022 60
FIGURE 15 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 61
FIGURE 16 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , CAGR (2023-2030) 61
FIGURE 17 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE 62
FIGURE 18 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2022 69
FIGURE 19 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2023-2030 (USD THOUSAND) 70
FIGURE 20 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, CAGR (2023-2030) 70
FIGURE 21 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, LIFELINE CURVE 71
FIGURE 22 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 77
FIGURE 23 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 78
FIGURE 24 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 78
FIGURE 25 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 79
FIGURE 26 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2022 84
FIGURE 27 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 85
FIGURE 28 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, CAGR (2023-2030) 85
FIGURE 29 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, LIFELINE CURVE 86
FIGURE 30 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 92
FIGURE 31 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 93
FIGURE 32 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 93
FIGURE 33 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 34 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SNAPSHOT 99
FIGURE 35 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 156